New drug cocktail aims to shrink Hard-to-Treat breast cancer
NCT ID NCT06756932
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- metastatic breast cancer whose disease has progressed after prior treatments. The main goals are to check safety and find the best dose, while also seeing if the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BGB-21447 (a Bcl-2 inhibitor) combined with fulvestrant and/or BGB-43395 (a CDK4 inhibitor)
- What this could lead to
- If successful, this could lead to a new treatment option for people with HR+/HER2- metastatic breast cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 120 participants, focused on safety and dosing. It is too small and early to know if the combination will work or be safe long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Calvary Mater Newcastle
RECRUITINGWaratah, New South Wales, NSW 2298, Australia
-
Fred Hutchinson Cancer Research Center
RECRUITINGSeattle, Washington, 98109-4433, United States
-
Fudan University Shanghai Cancer Centerpudong
RECRUITINGShanghai, Shanghai Municipality, 201321, China
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, WA 6009, Australia
-
Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-3907, United States
-
Peter Maccallum Cancer Centre
RECRUITINGMelbourne, Victoria, VIC 3000, Australia
-
Saint Vincents Hospital Sydney
RECRUITINGDarlinghurst, New South Wales, NSW 2010, Australia
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310016, China
-
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
RECRUITINGGuangzhou, Guangdong, 510245, China
-
Sunshine Coast University Private Hospital
RECRUITINGBirtinya, Queensland, QLD 4575, Australia
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
University of Iowa Hospitals and Clinics
RECRUITINGIowa City, Iowa, 52242-1009, United States
-
Western Health Sunshine Hospital
RECRUITINGSt Albans, Victoria, VIC 3021, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual therapy may ease breast cancer treatment side effects
- A gentle jog might be the key to better sleep for breast cancer survivors
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?